Biodesix closes on $5.2 million, plans to raise another $5 million
BOULDER — Biodesix Inc., a life-sciences company that does molecular diagnostics tests, has closed on $5.28 million in capital.
The company raised the funds through convertible promissory notes and equity securities issuable upon the conversion of the notes, according to a Form D filed with the U.S. Securities and Exchange Commission on May 8.
CEO David Brunel told BizWest that the company plans to close on another $5 million in funding in the next few weeks.
SPONSORED CONTENT
Exploring & expressing grief
Support groups and events, as well as creative therapies and professional counseling, are all ways in which Pathways supports individuals dealing with grief and loss.
Biodesix, which makes blood-based molecular tests, is raising the capital because of its continuing growth, Brunel said.
BOULDER — Biodesix Inc., a life-sciences company that does molecular diagnostics tests, has closed on $5.28 million in capital.
The company raised the funds through convertible promissory notes and equity securities issuable upon the conversion of the notes, according to a Form D filed with the U.S. Securities and Exchange Commission on May 8.
CEO David Brunel told BizWest that the company plans to close on another $5 million in funding in the next few weeks.
Biodesix, which makes blood-based molecular tests, is raising the capital because of its continuing growth, Brunel said.…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
